Table 2

Plasma pharmacokinetic parameters (mean ± SD) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ), obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg, n = 6) formulated as a cyclodextrin-based solution (FLBZ-CDs) or a carboximethylcelullose suspension (FLBZ-CMC) to sheep (Experiment 1)
PHARMACOKINETIC PARAMETERS FLBZ R-FLBZ
FLBZ-CDs(1)i.r. treatment FLBZ-CMC(1)i.r. treatment FLBZ-CDs(2)i.a. treatment FLBZ-CDs(1)i.r. treatment FLBZ-CMC(1)i.r. treatment FLBZ-CDs(2)i.a. treatment
T½abs/for (h) 3.67 ± 1.57 2.92 ± 0.94 0.40 ± 1.43* 3.00 ±1.21 4.95 ± 1.72 0.90 ± 0.30*
Cmax (μg/mL) 0.05 ± 0.01 0.03 ± 0.01 0.07 ± 0.04* 0.23 ± 0.04 0.14 ± 0.03* 0.35 ± 0.09*
Tmax (h) 12.0 ± 3.79 12.5 ± 2.95 2.75 ± 2.36* 10.5 ± 4.93 11.5 ± 1.22 2.75 ± 1.50*
AUC0-t (μg.h/mL) 1.35 ± 0.34 0.78 ± 0.53 0.65 ± 0.29 6.82 ± 1.77 4.92 ± 1.46 3.83 ± 1.86*
T½el (h) 25.8 ± 14.0 19.2 ± 15.1 15.1 ± 8.27* 17.0 ± 5.19 18.4 ± 3.74 6.73 ± 3.70*
MRT (h) 41.6 ± 19.0 34.5 ± 20.3 19.7 ± 9.73* 28.8 ± 8.58 35.4 ± 3.90 10.8 ± 4.07*

The pharmacokinetic parameters obtained after the intra-abomasal (i.a.) administration of FLBZ (3.8 mg/kg, n = 4) formulated as a cyclodextrin-based solution (FLBZ-CDs), is also shown (Experiment 2). T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0-t: Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.

1Experiment 1: crossover design (n = 6) sheep were treated with the HPβCD-FLBZ solution (FLBZ-CDs) or the CMC-FLBZ suspension (FLBZ-CMC) by the i.r. route at the same dose rate (3.8 mg/kg).

2Experiment 2: intraabomasal (i.a.) administration of the FLBZ-CDs solution (3.8 mg/kg, n = 4).

Ceballos et al.

Ceballos et al. BMC Veterinary Research 2012 8:71   doi:10.1186/1746-6148-8-71

Open Data